Results 41 to 50 of about 10,512 (252)
Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis
Open Chemistry, 2019 Resistance to Dopamine agonists therapy is still a key factor that hinders the clinical treatment of prolactinoma. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets.
Lan Xiaolei +4 more
doaj +1 more source
Journal of Medical Case Reports, 2019 Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi +6 more
doaj +1 more source
AIMS Neuroscience, 2021 Pituitary prolactinoma is one of the most complicated and fatally pathogenic pituitary adenomas. Therefore, there is an urgent need to improve our understanding of the underlying molecular mechanism that drives the initiation, progression, and metastasis
Vikrant Ghatnatti +4 more
doaj +1 more source
Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. [PDF]
, 2021 While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a
Andereggen, Lukas +7 more
core +1 more source
Aggressive giant prolactinoma: a case report
Journal of Medical Case Reports, 2022 Background Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.
Marisa Khatijah Borhan +1 more
doaj +1 more source
Late presentation of acromegaly in medically controlled prolactinoma patients
Endocrinology, Diabetes & Metabolism Case Reports, 2016 Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion.
Ekaterina Manuylova +6 more
doaj +1 more source
Frontiers in Endocrinology, 2019 Context: Overall, giant prolactinomas are rare tumors (4%), especially those larger than 60 mm (1%). Despite the predominance of macroadenoma documented in multiple endocrine neoplasia type 1 (MEN1)-related prolactinoma, only three giant prolactinoma ...
Naiara C. B. Dantas +6 more
doaj +1 more source
Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence? [PDF]
, 2007 Juvenile cystinosis was diagnosed in a patient who presented with severe headache attacks and photophobia. Treatment with oral cysteamine and topical cysteamine eye drops was started.
Besouw, Martine T. P. +3 more
core +6 more sources
Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma
Medicine Science, 2015 It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently or due to obesity.
Mazhar Muslum Tuna +5 more
doaj +1 more source
The value of PRL in predicting prolactinοma in hyperprolactinemic PCOS [PDF]
, 2018 Background To identify a serum prolactin (PRL) cut‐off value indicative of a PRL‐producing adenoma in women with Polycystic Ovarian Syndrome (PCOS) and hyperprolactinemia and characterize such patients.
Angelousi, Anna +7 more
core +1 more source